What is the SUPN stock price?

Supernus Pharmaceuticals, Inc. (SUPN) last available close: $28.15, as of 11/3/26. Prices on Cylvex may be delayed.

How many analyst price targets for SUPN were reached?

5 of 9 published price targets for SUPN were reached within 12 months (56% reached); 1 is still open. Counts only — firm names and target values are shown to signed-in members.

How many firms publish price targets or ratings on SUPN?

5 firms have published price targets or ratings on SUPN that Cylvex tracks. Counts only — firm names and target values are shown to signed-in members.

Is this investment advice?

No. Cylvex is an educational and informational platform; nothing on this page is investment, financial or trading advice. Past analyst targets do not predict future results.

NASDAQ

Updated Nov 3, 7:59 PM ET

SUPN

Supernus Pharmaceuticals, Inc.

$28.26CS band Caution

−$13.77 (32.85%) At close $28.15 · Tue

☾After Hours +$0.11 (0.40%) Nov 3, 7:59 PM ET

About SUPN

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Cylvex Score

Caution

Multiple risk signals, limited coverage

Multi-factor score. Not a buy/sell signal.

Score history

Calibrating

Score history is calibrating — it appears once enough daily scores are recorded.

What goes into the score

6 axes · equal weight

AnalystWall Street consensus & target distance

GrowthEarnings growth trajectory

ProfitabilityROE, margins, cash generation

ValuationPE, PEG, price-to-book ratios

TechnicalsPrice momentum & 52-week position

RiskBeta, volatility, leverage

The Cylvex Score is a multi-factor summary for education. Not a buy/sell signal. Not investment advice.